MyFinsight
Home
Blog
About
Contact
Download
Download image
Sales and maturities
of short-term...
$122,000K
Proceeds from exercise of
stock options and...
$3K
Net cash provided by
(used in) investing...
$52,253K
Net cash provided by
financing activities
$3K
Canceled cashflow
$69,747K
Net increase
(decrease) in cash, cash...
$19,961K
Canceled cashflow
$32,295K
Purchases of short-term
investments
$69,747K
Deferred revenue
$16,537K
Stock-based compensation
expense
$4,308K
Accrued expenses
$574K
Accounts payable
$398K
Right-of-use asset -
operating lease
-$292K
Other non-cash items
-$77K
Net cash used in
operating activities
-$32,295K
Canceled cashflow
$22,186K
Net loss
-$31,643K
Accounts receivable
$17,243K
Prepaid expenses and
other assets
$4,525K
Amortization (accretion) of
premium (discount) on...
$764K
Operating lease
liabilities
-$306K
Back
Back
Cash Flow
source: myfinsight.com
Astria Therapeutics, Inc. (ATXS)
Astria Therapeutics, Inc. (ATXS)